Cardiac preconditioning during percutaneous coronary interventions

Cardiovascular Drugs and Therapy

Volumn 19, Issue 3, 2005, Pages 211-217

  Jneid, Hani ^a   Leessar, Massoud ^a   Bolli, Roberto ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Ischemia; Nitroglycerin; Percutaneous coronary intervention; Preconditioning; Stable angina

Indexed keywords

ADENOSINE; BRADYKININ; CREATINE KINASE; ESTROGEN; GLYCERYL TRINITRATE; NALOXONE; NICORANDIL; PHENTOLAMINE; PLACEBO; PRAVASTATIN;

ANGINA PECTORIS; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; CREATINE KINASE BLOOD LEVEL; ELECTROCARDIOGRAM; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HEART STRESS; HEART VENTRICLE WALL MOTION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; SCORING SYSTEM; ST SEGMENT;

ADENOSINE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BRADYKININ; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; NICORANDIL; NITROGLYCERIN; PRAVASTATIN;

EID: 24344435625     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-005-2466-8     Document Type: Review

References (59)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136.
2. Bolli R, Becker L, Gross G, Mentzer R, Jr., Balshaw D, Lathrop DA. Myocardial protection at a crossroads: The need for translation into clinical therapy. Circ Res 2004;95:125-134.
3. Leesar MA, Stoddard MF, Dawn B, Jasti VG, Masden R, Bolli R. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation 2001;103:2935-2941.
4. Smith SC, Jr., Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001;103:3019-3041.
5. Bolli R, Dawn B, Tang XL, et al. The nitric oxide hypothesis of late preconditioning. Basic Res Cardiol 1998;93:325-338.
6. Bolli R. The late phase of preconditioning. Circ Res 2000;87:972-983.
7. Stein AB, Tang X, Guo Y, Xuan YT, Dawn B, Bolli R. Delayed adaptation of the heart to stress: Late preconditioning. Stroke 2004;35:2676-2679.
8. Maybaum S, Ilan M, Mogilevsky J, Tzivoni D. Improvement in ischemic parameters during repeated exercise testing: A possible model for myocardial preconditioning. Am J Cardiol 1996;78:1087-1091.
9. Lambiase PD, Edwards RJ, Cusack MR, Bucknall CA, Redwood SR, Marber MS. Exercise-induced ischemia initiates the second window of protection in humans independent of collateral recruitment. J Am Coll Cardiol 2003;41:1174-1182.
10. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-251.
11. Abdelmeguid AE, Ellis SG, Sapp SK, Whitlow PL, Topol EJ. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J 1996;131:1097-1105.
12. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528-1536.
13. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. Jama 1997;277:461-466.
14. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl JMed 1994;330:956-9561.
15. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
16. Jneid H, Bhatt DL. Advances in antiplatelet therapy. Expert Opin Emerg Drugs 2003;8:349-363.
17. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922-928.
18. Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002;106:2180-2183.
19. Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: Impact on periprocedural myocardial infarction. Eur Heart J 2004;25:1822-1828.
20. Wolfrum S, Grimm M, Heidbreder M, et al. Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol 2003;41:474-480.
21. Birnbaum Y, Ashitkov T, Uretsky BF, Ballinger S, Motamedi M. Short-term atorvastatin pretreatment reduces myocardial infarct size in normocholesterolemic rats. J Am Coll Cardiol 2003;41:394.
22. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285-1290.
23. Taggart P, Yellon DM. Preconditioning and arrhythmias. Circulation 2002;106:2999-3001.
24. Airaksinen KE, Huikuri HV. Antiarrhythmic effect of repeated coronary occlusion during balloon angioplasty. J Am Coll Cardiol 1997;29:1035-1038.
25. Okishige K, Yamashita K, Yoshinaga H, et al. Electrophysiologic effects of ischemic preconditioning on QT dispersion during coronary angioplasty. J Am Coll Cardiol 1996;28:70-73.
26. Wu ZK, livainen T, Pehkonen E, Laurikka J, Tarkka MR. Ischemic preconditioning suppresses ventricular tachyarrhythmias after myocardial revascularization. Circulation 2002;106:3091-3096.
27. Laskey WK. Beneficial impact of preconditioning during PTCA on creatine kinase release. Circulation 1999;99:2085-2089.
28. Birincioglu M, Yang XM, Critz SD, Cohen MV, Downey JM. S-T segment voltage during sequential coronary occlusions is an unreliable marker of preconditioning. Am J Physiol 1999;277:H2435-H2441.
29. Leesar MA, Stoddard MF, Xuan YT, Tang XL, Bolli R. Non- electrocardiographic evidence that both ischemic preconditioning and adenosine preconditioning exist in humans. J Am Coll Cardiol 2003;42:437-445.
30. Shattock MJ, Lawson CS, Hearse DJ, Downey JM. Electrophysiological characteristics of repetitive ischemic preconditioning in the pig heart. J Mol Cell Cardiol 1996;28:1339-1347.
31. Cohen MV, Yang XM, Downey JM. Attenuation of S-T segment elevation during repetitive coronary occlusions truly reflects the protection of ischemic preconditioning and is not an epiphenomenon. Basic Res Cardiol 1997;92:426-434.
32. Leesar MA, Stoddard M, Ahmed M, Broadbent J, Bolli R. Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation 1997;95:2500-2507.
33. Strauer BE, Heidland UE, Heintzen MP, Schwartzkopff B. Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: Impact on hemodynamic function and left ventricular performance. J Am Coll Cardiol 1996;28:1119-1126.
34. Kerensky RA, Kutcher MA, Braden GA, Applegate RJ, Solis GA, Little WC. The effects of intracoronary adenosine on preconditioning during coronary angioplasty. Clin Cardiol 1995;18:91-96.
35. Heidland UE, Heintzen MP, Michel CJ, Strauer BE. Effect of adjunctive intracoronary adenosine on myocardial ischemia, hemodynamic function and left ventricular performance during percutaneous transluminal coronary angioplasty: Clinical access to ischemic preconditioning? Coron Artery Dis 2000;11:421-428.
36. Heidland UE, Heintzen MP, Schwartzkopff B, Strauer BE. Preconditioning during percutaneous transluminal coronary angioplasty by endogenous and exogenous adenosine. Am Heart J 2000;140:813-820.
37. Heidland UE, Heintzen MP, Michel CJ, Strauer BE. Intracoronary administration of dipyridamole prior to percutaneous transluminal coronary angioplasty provides a protective effect exceeding that of ischemic preconditioning. Coron Artery Dis 2000;11:607-613.
38. Schaefer S, Correa SD, Valente RJ, Laslett LJ. Blockade of adenosine receptors with aminophylline limits ischemic preconditioning in human beings. Am Heart J 2001;142:E4.
39. Desmet WJ, Dens J, Coussement P, Van de Werf F. Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial. ADEnosine Limit myocardial Necrosis. Heart 2002;88:293-295.
40. Kopecky SL, Aviles RJ, Bell MR, et al. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: The ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J 2003;146:146-152.
41. Bolli R, Manchikalapudi S, Tang XL, et al. The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning. Circ Res 1997;81:1094-1107.
42. Qiu Y, Rizvi A, Tang XL, et al. Nitric oxide triggers late preconditioning against myocardial infarction in conscious rabbits. Am J Physiol 1997;273:H2931-H2936.
43. Markham A, Plosker GL, Goa KL. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 2000;60:955-974.
44. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989;63:18J-24J.
45. Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994;90:700-705.
46. Matsubara T, Minatoguchi S, Matsuo H, et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol 2000;35:345-351.
47. Kato T, Kamiyama T, Maruyama Y, Tanaka S, Yoshimoto N. Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty. Am Heart J 2001;141:940-943.
48. Matsuo H, Watanabe S, Segawa T, et al. Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATP-sensitive K+ channel opener nicorandil. Bur Heart J 2003;24:1296-1303.
49. Yasuda T, Hashimura K, Matsu-ura Y, et al. Nicorandil, a hybrid between nitrate and ATP-sensitive potassium channel opener, preconditions human heart to ischemia during percutaneous transluminal coronary angioplasty. Jpn Circ J 2001;65:526-530.
50. Sakai K, Yamagata T, Teragawa H, Matsuura H, Chayama K. Nicorandil-induced preconditioning as evidenced by troponin T measurements after coronary angioplasty in patients with stable angina pectoris. Jpn Heart J 2002;43:443-453.
51. Sakai K, Yamagata T, Teragawa H, Matsuura H, Chayama K. Nicorandil enhances myocardial tolerance to ischemia without progressive collateral recruitment during coronary angioplasty. Circ J 2002;66:317-322.
52. Leesar MA, Stoddard MF, Manchikalapudi S, Bolli R. Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. J Am Coll Cardiol 1999;34:639-650.
53. Parratt JR, Vegh A, Zeitlin IJ, et al. Bradykinin and endothelial-cardiac myocyte interactions in ischemic preconditioning. Am J Cardiol 1997;80:124A-131A.
54. Parratt JR, Vegh A, Papp JG. Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning - a brief review of the evidence. Can J Physiol Pharmacol 1995;73:837-842.
55. Parratt JR. Protection of the heart by ischaemic preconditioning: Mechanisms and possibilities for pharmacological exploitation. Trends Pharmacol Sci 1994;15:19-25.
56. Lee TM, Su SF, Chou TF, Tsai CH. Effect of pravastatin on myocardial protection during coronary angioplasty and the role of adenosine. Am J Cardiol 2001;88:1108-1113.
57. Tomai F, Crea F, Gaspardone A, et al. Phentolamine prevents adaptation to ischemia during coronary angioplasty: Role of alpha-adrenergic receptors in ischemic preconditioning. Circulation 1997;96:2171-2177.
58. Tomai F, Crea F, Gaspardone A, et al. Effects of naloxone on myocardial ischemic preconditioning in humans. J Am Coll Cardiol 1999;33:1863-1869.
59. Lee TM, Su SF, Chou TF, Tsai CH. Pharmacologic preconditioning of estrogen by activation of the myocardial adenosine triphosphate-sensitive potassium channel in patients undergoing coronary angioplasty. J Am Coll Cardiol 2002;39:871-877.